Glioblastoma, Idh-Wildtype Clinical Trials
2 recruiting trials for Glioblastoma, Idh-Wildtype. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Glioblastoma, Idh-Wildtype clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by ECOG-ACRIN Cancer Research Group (1), Jasper Gerritsen (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (procedure, 1 trial), followed by Fluciclovine F18, Gadolinium-Chelate.
Track Glioblastoma, Idh-Wildtype trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE...
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors...
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Glioblastoma, Idh-Wildtype, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Glioblastoma, Idh-Wildtype, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Glioblastoma, Idh-Wildtype, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.